Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome

被引:36
作者
Zegri-Reiriz, Isabel [1 ]
Javier de Haro-del Moral, F. [2 ]
Dominguez, Fernando [1 ,3 ,4 ]
Salas, Clara [3 ,5 ]
de la Cuadra, Pablo [6 ]
Plaza, Aresio [7 ]
Krsnik, Isabel [8 ]
Gonzalez-Lopez, Esther [1 ,3 ,4 ]
Garcia-Pavia, Pablo [1 ,3 ,9 ]
机构
[1] Hosp Univ Puerta Hierro, Dept Cardiol, Manuel Falla 2, Madrid 28222, Spain
[2] Hosp Univ Puerta Hierro, Dept Nucl Med, Madrid, Spain
[3] CIBER Cardiovasc Dis CIBERCV, Madrid, Spain
[4] CNIC, Myocardial Biol Programme, Madrid, Spain
[5] Hosp Univ Puerta Hierro, Dept Pathol, Madrid, Spain
[6] Hosp Univ Puerta Hierro, Dept Orthopaed & Traumatol, Madrid, Spain
[7] Hosp Univ Puerta Hierro, Dept Immunol, Madrid, Spain
[8] Hosp Univ Puerta Hierro, Dept Hematol, Madrid, Spain
[9] UFV, Madrid, Spain
关键词
Amyloidosis; Tansthyretin; Carpal tunnel syndrome; TRANSTHYRETIN; DIAGNOSIS;
D O I
10.1007/s12265-019-09895-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carpal tunnel syndrome (CTS) is a common finding among patients with cardiac amyloidosis. We sought to determine the prevalence of cardiac amyloidosis in patients who had undergone CTS surgery. From 2005 to 2014, 308 patients >= 60 years underwent CTS surgery. Of these, 233 (76%) agreed to participate in the study and 101 (73 +/- 8 years; 68% females) showed left ventricular hypertrophy (LVH) >= 12 mm and underwent additional studies to diagnose AL and ATTR amyloidosis. Based on complementary studies, three patients were diagnosed with cardiac amyloidosis (two wild-type ATTR and one AL). The three patients showed bilateral CTS with no occupational risk factors. Prevalence of cardiac amyloidosis in the overall cohort was only 1.2% (3/233), but among patients with LVH and bilateral CTS, the prevalence was 5.5% (3/55) and 13.6% (3/22) if cases with an occupational risk factor were excluded. Cardiac amyloidosis should be excluded in the presence of bilateral CTS and particularly if an occupational risk factor is absent.
引用
收藏
页码:507 / 513
页数:7
相关论文
共 15 条
  • [1] Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy
    Ackermann, Elizabeth J.
    Guo, Shuling
    Booten, Sheri
    Alvarado, Luis
    Benson, Merrill
    Hughes, Steve
    Monia, Brett P.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2012, 19 : 43 - 44
  • [2] Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
    Coelho, Teresa
    Maia, Luis F.
    da Silva, Ana Martins
    Cruz, Marcia Waddington
    Plante-Bordeneuve, Violaine
    Lozeron, Pierre
    Suhr, Ole B.
    Campistol, Josep M.
    Conceicao, Isabel Maria
    Schmidt, Hartmut H. -J.
    Trigo, Pedro
    Kelly, Jeffery W.
    Labaudinie, Richard
    Chan, Jason
    Packman, Jeff
    Wilson, Amy
    Grogan, Donna R.
    [J]. NEUROLOGY, 2012, 79 (08) : 785 - 792
  • [3] Cardiac amyloidosis : An update on diagnosis and treatment
    Donnelly, Joseph P.
    Hanna, Mazen
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2017, 84 : 12 - 26
  • [4] Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis
    Geller, Hallie I.
    Singh, Avinainder
    Alexander, Kevin M.
    Mirto, Tara M.
    Falk, Rodney H.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (10): : 962 - 963
  • [5] Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
    Gillmore, Julian D.
    Maurer, Mathew S.
    Falk, Rodney H.
    Merlini, Giampaolo
    Damy, Thibaud
    Dispenzieri, Angela
    Wechalekar, Ashutosh D.
    Berk, John L.
    Quarta, Candida C.
    Grogan, Martha
    Lachmann, Helen J.
    Bokhari, Sabahat
    Castano, Adam
    Dorbala, Sharmila
    Johnson, Geoff B.
    Glaudemans, Andor W. J. M.
    Rezk, Tamer
    Fontana, Marianna
    Palladini, Giovanni
    Milani, Paolo
    Guidalotti, Pierluigi L.
    Flatman, Katarina
    Lane, Thirusha
    Vonberg, Frederick W.
    Whelan, Carol J.
    Moon, James C.
    Ruberg, Frederick L.
    Miller, Edward J.
    Hutt, David F.
    Hazenberg, Bouke P.
    Rapezzi, Claudio
    Hawkins, Philip N.
    [J]. CIRCULATION, 2016, 133 (24) : 2404 - +
  • [6] González-López E, 2017, REV ESP CARDIOL, V70, P991, DOI [10.1016/j.rec.2017.05.036, 10.1016/j.recesp.2017.05.018]
  • [7] Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disprovingmyths
    Gonzalez-Lopez, Esther
    Gagliardi, Christian
    Dominguez, Fernando
    Quarta, Cristina Candida
    Javier de Haro-del Moral, F.
    Milandri, Agnese
    Salas, Clara
    Cinelli, Mario
    Cobo-Marcos, Marta
    Lorenzini, Massimiliano
    Lara-Pezzi, Enrique
    Foffi, Serena
    Alonso-Pulpon, Luis
    Rapezzi, Claudio
    Garcia-Pavia, Pablo
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 (24) : 1895 - 1904
  • [8] Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
    Gonzalez-Lopez, Esther
    Gallego-Delgado, Maria
    Guzzo-Merello, Gonzalo
    de Haro-del Moral, F. Javier
    Cobo-Marcos, Marta
    Robles, Carolina
    Bornstein, Belen
    Salas, Clara
    Lara-Pezzi, Enrique
    Alonso-Pulpon, Luis
    Garcia-Pavia, Pablo
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (38) : 2585 - 2594
  • [9] de Haro-del Moral F, 2012, REV ESP CARDIOL, V65, P440, DOI [10.1016/j.rec.2011.12.016, 10.1016/j.recesp.2011.12.015]
  • [10] Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
    Lousada, Isabelle
    Comenzo, Raymond L.
    Landau, Heather
    Guthrie, Spencer
    Merlini, Giampaolo
    [J]. ADVANCES IN THERAPY, 2015, 32 (10) : 920 - 928